Newswise — BOSTON – Relapse of disease following conventional treatments remains one of the central problems in cancer management, yet few therapeutic agents targeting drug resistance and tolerance exist. New research conducted at the Cancer Center at Beth Israel Deaconess Medical Center found that a microRNA – a small fragment of non-coding genetic material that regulates gene expression – mediates drug tolerance in lung cancers with a specific mutation. The findings, published today in Nature Metabolism, suggest that the microRNA could serve as a potential target for reversing and preventing drug tolerance in a subset of non-small-cell lung cancers.
“These results were a surprise and represent a total novel finding in the area,” said senior author Frank J. Slack, PhD, Director of the HMS Initiative for RNA Medicine at the Cancer Center at BIDMC. “We have identified a novel pathway required for drug tolerance that is regulated by a microRNA. Targeting this microRNA reduces tolerance, suggesting a potential new approach for treatment of lung cancer.”
Lung cancer is the leading causes of cancer-related deaths among both men and women. As a class, non-small cell lung cancers – which comprise about 85 percent of lung cancer diagnoses – tend to be less aggressive but harder to treat than small cell lung cancers. About one in 10 non-small-cell lung carcinomas carries a mutation to a protein called EGFR on the surface of the cancer’s cells.
Since 2003, several medications that block the activity of the EGFR protein – a class of drugs called tyrosine kinase inhibitors – have received FDA-approval for the treatment of EGFR-positive lung cancers. However, despite patients’ sometimes dramatic initial response to these medications, many patients eventually relapse as their cancer develops resistance to the treatment. By studying drug resistant tumor cells, Slack and colleagues identified the key players driving the development of drug resistance.
“In this study, we discovered that a microRNA known as miR-147b is a critical mediator of resistance among a subpopulation of tumor cells that adopt a tolerance strategy to defend against EGFR-based anticancer treatments,” said Slack, who is also the Shields Warren Mallinckrodt Professor of Medical Research, Departments of Pathology and Medicine, Harvard Medical School. “We are currently testing the idea of targeting this new pathway as a therapy in clinically relevant mouse models of EGFR-mutant lung cancer.”
In addition to Slack, authors include Wen Cai Zhang, He Huang, Min Yuan, Tanvi Saxena, John M. Asara and Daniel B. Costa of BIDMC; Julie M. Wells, Kin-Hoe Chow of Jackson Laboratory for Mammalian Genetics; Mary Ann Melnick and Katerina Politi of Yale University School of Medicine.
This work was supported by NIH-YALE SPORE in Lung Cancer grants P50CA196530 and P50CA196530-03S1; NIH-YALE SPORE in Lung Cancer Career Development Program Award, the BIDMC-JAX collaboration project; the Ludwig Center at Harvard; the National Institutes of Health (grants P30CA034196, 5P01CA120964 and 5P01CA006516); and NRSA grant 5T32HL007893-20. The authors declare no competing interests.
Written by Jacqueline Mitchell, Beth Israel Deaconess Medical Center